Objective: The present study aimed to evaluate alterations in the levels of iron, divalent metal transporter 1 (DMT1) with the iron-responsive element (IRE), transferrin receptor 1 (TfR1), ferroportin 1 (FPN1), and iron regulatory protein 1 (IRP1) in the temporal cortex of human brains with Parkinson disease (PD).
Postmortem studies have demonstrated that iron selectively accumulates in the substantia nigra (SN) of patients with Parkinson disease (PD). 1 The dysregulation of iron transporters is thought to contribute to iron deposition in PD. Recently, increased expression of the iron importer divalent metal transporter 1 (DMT1) with the iron-responsive element (IRE, DMT1+IRE) has been reported in the SN of postmortem PD brains. 2 Meanwhile, the downregulation of ferroportin 1 (FPN1), an iron exporter, was also suggested to be related to 6-hydroxydopamineinduced nigral iron accumulation. 3 However, it is unknown whether iron metabolism is disrupted in brain regions other than the SN (e.g., the cerebral cortex) and how this occurs. In this study, we investigated iron content in the temporal cortex of postmortem PD brains. Unexpectedly, we observed decreased iron content in this brain region in PD but not in Alzheimer disease (AD). To investigate the underlying mechanism, we further evaluated alterations in transporter expression, particularly DMT11IRE, FPN1, and transferrin receptor 1 (TfR1). In PD brains, we observed decreased protein levels of DMT11IRE, FPN1, and TfR1, and decreased expression of iron regulatory protein 1 (IRP1) in the cortex. These results imply that a different iron regulatory mechanism may exist in the temporal cortex, and that iron redistribution might occur between the cortex and SN in PD.
Arizona. 4 The mean postmortem interval for this study was 2.6 hours. A clinical diagnosis was established according to the UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria for PD, or the National Institute of Neurological and Communicative Disorders and Stroke criteria for AD. Healthy controls (HC) were selected based on age and no history of neuropathological diagnosis of neurologic or psychiatric disease. The HC were followed up clinically for 3 years to exclude the development of any neurodegenerative disease. The study population consisted of 10 cognitive HC subjects (4 male and 6 female; mean age 84.6 6 1.45 years, range 78-92 years), 10 patients with PD (6 male and 4 female; mean age 82.7 6 1.65 years, range 72-90 years), and 10 patients with AD (3 male and 7 female; mean age 84.1 6 1.84 years, range 78-91 years).
Assessment of iron content. Temporal cortex tissue (20 mg) was isolated from each brain and lysed with nitric acid. After adjusting the volume to 2 mL, the levels of iron and other metals were measured using an ICP-MS 7500CE (Agilent, Santa Clara, CA) inductively coupled plasma mass spectrometer.
Western blotting analysis. A total of 80 mg of protein from each sample was separated using 8% sodium dodecyl sulfatepolyacrylamide gels and then transferred by electroblotting to polyvinylidene difluoride membranes. After 2 hours of blocking with 10% nonfat milk at room temperature, the membranes were incubated with primary antibody against DMT11IRE, IRP1, TfR1, or FPN1 overnight at 4°C, followed by incubation with secondary antibody conjugated to horseradish peroxidase. b-Actin was used as a loading control. Crossreactivity was visualized by enhanced chemiluminescence Western blotting detection reagents and then analyzed through scanning densitometry with a Tanon Image System (Tanon, Shanghai, China).
Standard protocol approvals, registration, and patient consent. Human tissues were collected with informed consent from subjects or next of kin and with ethical approval from the Banner Sun Health Institutional Review Board prior to the autopsy.
Statistical analysis. The data were presented as mean 6 SEM. A one-way analysis of variance followed by the Dunnett test was used to compare metal content between different groups. An unpairedsamples t test was used to compare differences in protein levels. A probability value of p , 0.05 was considered statistically significant.
RESULTS Iron content was lower in the temporal cortex of postmortem PD brains. Among the 4 metal ions measured, iron was abundant, but only trace amounts of the other 3 were detected. The iron levels in postmortem PD brains were much lower compared with those of HC (table) . However, no changes were observed in the temporal cortex of postmortem AD brains. There was no difference for Mn, Ni, and Cu among the 3 groups.
Expression levels of DMT11IRE, TfR1, FPN1, and IRP1 were decreased in the temporal cortex of PD brains. To investigate whether iron-related protein expression affected iron levels, we determined the expression levels of DMT11IRE, TfR1, FPN1, and IRP1. We observed that these proteins were all downregulated in PD brains when compared with HC ( figure) . There was some overlap where some DMT1IRE and FPN1 levels were higher in a few PD brains than some control counterparts; however, on average there was a reduction in the levels in the PD cortex that showed statistical relevance. In PD brains, the protein levels were 22.22% (DMT1), 14.23% (TfR1), 21.11% (FPN1), and 36.9% (IRP1) lower than those in controls. No changes were observed in AD brains compared with HC (data not shown). DISCUSSION The abnormal distribution of transition metal ions in specific brain regions has been reported in patients with neurodegenerative disorders, including PD and AD. Although elevated iron has been previously examined extensively in PD, we observed decreased iron levels in the temporal cortex of postmortem PD brains but not AD brains. However, this result was not consistent with a previous study, 5 which reported no significant differences in the level of total iron in the cortex (Brodmann area 21) between parkinsonian patients and age-matched controls. This discrepancy between the 2 studies might be due to the different measurement methods, severity stages, and race. Because iron misdistribution might be involved in several different disorders, 6 we supposed that iron redistribution might exist in PD brains, particularly between the temporal cortex and the SN.
Several proteins responsible for intracellular iron homeostasis might be involved in iron metabolism disruption in the cerebral cortex. We first focused on DMT11IRE, which possesses an IRE sequence in the 39-untranslated region and is responsive to iron through an IRE/IRP-dependent mechanism. Normally when the intracellular iron level decreased, DMT11IRE was upregulated by enhanced IRP1 binding to the IRE to maintain iron homeostasis. However, this regulatory mechanism obviously failed to explain our findings that both iron and IRP1/ DMT11IRE levels were decreased in the temporal cortex of PD brains. Therefore, DMT11IRE downregulation might be the primary cause of the iron deprivation observed in the PD temporal cortex and not a secondary event. Contrary to an unchanged IRP1 binding activity found in the SN of PD brains, 7 we supposed that with a lower IRP1 protein level, the affinity of IRP1 binding to the IRE must be impaired, eventually leading to decreased DMT11IRE and TfR1 expression in the temporal cortex of PD brains. Our previous studies showing that DMT11IRE downregulation could be initiated by IRP1 knockdown may further confirm this notion. 8 Abnormal cerebral perfusion occurs in PD. 9 Hypoxia and other factors have been reported to suppress IRP/IRE binding affinity and to induce the downregulation of IRPs. 10 We believe as an iron exporter, even FPN1 downregulation was a compensatory mechanism to partially offset reduced DMT11IRE and iron import; however, this might fail to counteract the preceding process of iron deprivation. In this study, we showed that the downregulation of DMTI1IRE, TfR1, FPN1, and IRP1 contributed to decreased iron content in the temporal cortex of PD brains. These findings also suggest that iron homeostasis is disrupted through different mechanisms in the SN and temporal cortex. Science Foundation of China (81171207), and Fok Ying Tong Education Foundation (121034). J. Xie received research supports from 973 program (2011CB504102) and National Natural Science Foundation of China (30930036). Go to Neurology.org for full disclosures.
